A cohort of the adagrasib KRYSTAL-01 study is evaluating adagrasib in previously untreated KRAS G12C/STK11 co-mutated NSCLC as this disease subset has poor prognosis with chemotherapy or immunotherapy and is an area of unmet need. This evidence concerns the gene KRAS and non-small cell lung carcinoma.